Development of a novel glycoengineering platform for the rapid production of conjugate vaccines
Preprint
Abstract
Antimicrobial resistance (AMR) is threatening the lives of millions worldwide. Antibiotics which once saved countless lives, are now failing, ushering in vaccines development as a current global imperative. Conjugate vaccines produced either by chemical synthesis or biologically in Escherichia coli cells, have been demonstrated to be safe and efficacious in protection against several deadly bacterial diseases. However, conjugate vaccines assembly and production have several shortcomings which hinders their wider availability. Here, we developed a tool, Mobile-element Assisted Glycoconjugation by Insertion on Chromosome, MAGIC, a novel method that overcomes the limitations of the current conjugate vaccine design method(s). We demonstrate at least 2-fold increase in glycoconjugate yield via MAGIC when compared to conventional bioconjugate method(s). Furthermore, the modularity of the MAGIC platform also allowed us to perform glycoengineering in genetically intractable bacterial species other than E. coli . The MAGIC system promises a rapid, robust and versatile method to develop vaccines against bacteria, especially AMR pathogens, and could be applied for biopreparedness.Keywords
All Related Versions
- Published version: Microbial Cell Factories, 22 (1), 1.
This publication has 29 references indexed in Scilit:
- Exploitation of bacterialN-linked glycosylation to develop a novel recombinant glycoconjugate vaccine againstFrancisella tularensisOpen Biology, 2013
- A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine designNature Medicine, 2011
- Simultaneous Glycan-Peptide Characterization Using Hydrophilic Interaction Chromatography and Parallel Fragmentation by CID, Higher Energy Collisional Dissociation, and Electron Transfer Dissociation MS Applied to the N-Linked Glycoproteome of Campylobacter jejuniMolecular & Cellular Proteomics, 2011
- Production of glycoprotein vaccines in Escherichia coliMicrobial Cell Factories, 2010
- Measuring the activity of BioBrick promoters using an in vivo reference standardJournal of Biological Engineering, 2009
- Two distinct but interchangeable mechanisms for flipping of lipid‐linked oligosaccharidesThe EMBO Journal, 2006
- Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coliProceedings of the National Academy of Sciences, 2005
- Tularaemia: bioterrorism defence renews interest in Francisella tularensisNature Reviews Microbiology, 2004
- Serological cross-reaction between the lipopolysaccharide O-polysaccharide antigens ofEscherichia coliO157:H7 and strains ofCitrobacter freundiiandCitrobacter sedlakiiFEMS Microbiology Letters, 2000
- A set of compatible tac promoter expression vectorsGene, 1996